hotspot -WSS

hotspot

author：Wikipedia 2025-09-28 23:47:50 - browse：25

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on Monday:

Should the patients who receive the medicine be limited based on PET scans of a protein called tau that Eli Lilly used as a key criteria for trying to determine whether they should receive the drug? That could reduce usage of the medicine by adding a barrier to its use.

And how do the potential risks of using the drug compare to its benefits? The FDA points to one analysis, admittedly with missing data, that could indicate patients who receive the drug have a higher risk of dying.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Regeneron agrees to White House price limits on anti

explore

WSS

Novo: Oral version of Ozempic leads to 15% weight loss

FDA panel endorses Alnylam’s heart drug — after picking it apart

Long Covid needs a new name — and a new frame

Biogen nominates mother of director’s child to replace him on board

Biogen nominates mother of director’s child to replace him on board

Can medical device makers keep up in the race to treat obesity?

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Supreme Court strikes down use of affirmative action

Biden administration plans revamp of organ transplant system

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Senate panel passes drug pricing bills, but drops one PBM reform

How one medical school became remarkably diverse

FDA panel endorses Alnylam’s heart drug — after picking it apart

How one medical school became remarkably diverse

New weight loss drugs vying to be the next Wegovy or Mounjaro

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

entertainment

New weight loss drugs vying to be the next Wegovy or Mounjaro

Generate Biomedicines machine learning biotech raises $273M

Regeneron agrees to White House price limits on anti

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

New Covid vaccine is recommended for everyone 6 months or older

Telehealth for opioid use disorder is lifesaving

focus

focus

explore

focus